Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide (Ambrilia Biopharma Inc.)
- Development stage
- Approved
- Lead developer
- Ambrilia Biopharma
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
C2L-OCT-01 PR is a prolonged-release formulation of octreotide acetate, a synthetic somatostatin analog, developed by Ambrilia Biopharma. It was engineered using the company's proprietary C2L (Controlled Release) technology to provide a sustained therapeutic effect, allowing for extended dosing intervals of every 4 to 6 weeks, compared to the standard monthly administration of conventional long-acting formulations like Sandostatin LAR. The drug was primarily investigated for the treatment of acromegaly, a condition caused by excessive growth hormone production. Clinical development reached Phase 3, but the program was terminated following Ambrilia Biopharma's financial difficulties and subsequent restructuring in 2009.
- Other names
- octreotide acetate prolonged releaseoctreotide PR
02
Targets
SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on octreotide (Ambrilia Biopharma Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide (Ambrilia Biopharma Inc.).